Advent Life Sciences’ Post

Adenoid Cystic Carcinoma Market to Grow at a Substantial Growth Rate During the Forecast Period | HLB, Ayala Pharma, Merck, Amgen, CureVac, Actuate Therapeutics: Adenoid Cystic Carcinoma Market According to DelveInsight, the dynamics of the Adenoid Cystic Carcinoma market are expected to evolve in the coming years due to the anticipated introduction of new therapies, increased awareness of the disease, and advancements in research … Continue reading → #Business #Europe #HealthMedicine #PharmaceuticalsBiotech #US

📢 Confo Therapeutics Raises $60M to Advance Agonistic GPCR Antibodies 📢 Confo Therapeutics has successfully raised over $60 million in a Series B funding round, led by Ackermans & van Haaren. This significant funding will propel the company's innovative work in agonistic GPCR antibodies. Key Highlights: -Fund Allocation: Proceeds will support two Phase 1 studies and advance two additional programs up to IND/CTA. -R&D Focus: Enhanced efforts in discovering new candidates for rare endocrinal diseases and obesity. -Technology: Leveraging ConfoBodies to generate drug-like molecules and therapeutic antibodies targeting GPCRs. Cedric Ververken, CEO of Confo Therapeutics, stated, “Our platform stands out for its ability to discover agonists, either as small molecules or antibodies. We aim to develop new therapies for severe rare endocrine diseases and next-gen obesity drugs.” With the enormous success of GPCR-targeting drugs in diabetes and obesity, Confo Therapeutics is poised to make significant advancements in this area. Stay tuned for further updates as Confo continues to lead in GPCR modulation. #ConfoTherapeutics #FundingNews #GPCR #Biotech #PharmaInnovation #EndocrineDiseases #ObesityTreatment #DrugDiscovery #LifeSciences #HealthcareInnovation

We are excited to announce Deciduous Therapeutics as a Tier 3 Sponsor of the 11th Aging Research & Drug Discovery Meeting. Deciduous Therapeutics is a San Francisco based, venture backed start-up focused on harnessing the immune system to treat diseases of aging. Specifically, the company is focused on restoring natural killer t-cell function to systemically ablate pathological senescent cells. The company had demonstrated that a single dose of its proprietary NKT agonist is able to selectively remove senescent cells, resulting in disease resolution in both fibrosis and metabolic disease models. #ARDD2024 will feature a dynamic mix of academic institutions, clinicians, industry leaders, and pharmaceutical companies, fostering rich dialogues and unveiling new research in the field of aging. Mark your calendars for August 26-30, 2024 and register now at agingpharma.org https://lnkd.in/ggNnNTeh #ARDD2024 #DrugDiscovery #AgingResearch

We are very excited to expand our pipeline with the potential of best-in-class therapeutics for patients being underserved by existing treatment options in multiple inflammatory diseases. We have now secured the exclusive rights to develop and commercialize a Phase 2-ready IL-18 targeted fusion protein from #AprilBio. This long-acting injectable fusion protein is designed to neutralize the signal pathway of IL-18 for the regulation of inflammation. The Phase 1 trial demonstrated good safety and tolerability, favorable pharmacokinetics, and target engagement and we are ready to initiate on a Phase 2 clinical trial in first half of 2025. https://lnkd.in/gKgQV2H6

Novartis is building up its pipeline of inflammatory disorder drugs with the acquisition of IFM Due (IFM Therapeutics). The two companies collaborated in the preclinical research of molecules targeting the cGAS-STING pathway, which is associated with inflammation. #pharmaceuticalindustry #drugdevelopment #biopharma #biotechnology #researchanddevelopment #inflammation #clinicaltrials #strategicpartnerships #preclinicalresearch #preclinicalcollab

We are delighted to provide our first business update since delisting from AIM earlier this year and continue our journey from a discovery to an immuno-inflammation therapeutics company. We're making important progress with our small molecule drug discovery portfolio in immuno-inflammatory diseases, focusing on areas with significant unmet need and commercial potential. Our lead oral a4b7 integrin inhibitor for inflammatory bowel disease is nearing pre-clinical candidate selection, with planning for IND-enabling studies well underway. And we announce two new pipeline programmes which are progressing towards Lead Optimisation, with first-in-class and best-in-class potential. Elsewhere we are applying our PatientSeek platform to define a genetic fingerprint as a predictive biomarker for a4b7 response that will allow us to specifically design our pivotal clinical trials for success. Read more here:  https://lnkd.in/dbBTEKZx #C4XD #immuno_inflammation #biotech #innovation 

𝐎𝐥𝐢𝐠𝐨𝐧𝐮𝐜𝐥𝐞𝐨𝐭𝐢𝐝𝐞 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 𝐌𝐚𝐫𝐤𝐞𝐭: 𝐒𝐢𝐳𝐞, 𝐒𝐡𝐚𝐫𝐞 & 𝐅𝐨𝐫𝐞𝐜𝐚𝐬𝐭𝐬 2024-2031 𝐆𝐞𝐭 𝐅𝐫𝐞𝐞 𝐀𝐜𝐜𝐞𝐬𝐬 𝐭𝐨 𝐃𝐞𝐦𝐨 𝐑𝐞𝐩𝐨𝐫𝐭, 𝐄𝐱𝐜𝐞𝐥 𝐏𝐢𝐯𝐨𝐭 𝐚𝐧𝐝 𝐓𝐨𝐂: https://lnkd.in/dnCwD8vC #OligonucleotideTherapy Market Size is valued at USD 5.21 billion in 2023 and is predicted to reach USD 19.92 billion by the year 2031 at a 18.6% CAGR during the forecast period for 2024-2031. ▪ 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 𝐂𝐨𝐯𝐞𝐫𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 𝐚𝐫𝐞: ▪ BPCI ▪ SomaGenics, Inc. ▪ Hepion Pharmaceuticals ▪ Alnylam Pharmaceuticals ▪ Regulus Therapeutics ▪ Ionis Pharmaceuticals, Inc. ▪ Gilead Sciences ▪ Santaris ▪ DAC TECHNOLOGIES GROUP INTERNA ▪ Mirage ▪ Biogen ▪ Merck KGaA, Darmstadt, Germany ▪ Pfizer #Biotech #Pharmaceuticals #RNA #GeneTherapy #MedicalResearch #Oncology #NeurodegenerativeDiseases #InfectiousDiseases

As per DelveInsight Business Research LLP's analysis, the overall incident population of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) in the 7MM was reported as ~23K in 2020, which is expected to increase in the upcoming years. The Gastroenteropancreatic Neuroendocrine Tumors market size reached ~USD 3 billion in 2020 across the 7MM and is anticipated to grow with a significant CAGR by 2032. Some of the leading players in the Gastroenteropancreatic Neuroendocrine Tumors Market include Eli Lilly and Company, Phanes Therapeutics, Inc., Novatek Pharmaceuticals Ltd., Camurus, Advanced Accelerator Applications, RayzeBio, Aadi Bioscience, Inc., PharmaMar, and others. Read More: https://lnkd.in/gdm3HumV #healthcare #biotechnology #lifesciences #pharmaceuticalindustry #pharmaceutical #marketresearch #marketforecast #markettrends #consulting #healthcareconsulting #consultingservices #marketforecast

Pantherna Announces Research collaboration with Bayer to Advance LNP Technology for Beyond Liver mRNA Therapy Pantherna Therapeutics GmbH, a mRNA-lipid nanoparticle (LNP) platform company dedicated to the research and development of innovative mRNA-based therapeutics today announced a research collaboration with Bayer, investigating novel LNP-carriers for future mRNA therapies outside the liver. By combining their expertise in RNA therapeutics, both parties intend to identify novel LNP formulations that surpass the performance of conventional neutral LNPs as used in the mRNA vaccines. These advanced LNPs will be designed to potentially offer superior properties, ensuring the desired pharmacological outcomes and facilitating a smooth scalable translation towards development.  Ansgar Santel, CEO of Pantherna Therapeutics, commented “Pantherna values Bayer's trust in our technology and expertise. In collaboration, we will explore the potential of novel LNP formulations tailored to Bayer's therapeutic interest, accelerating the pace of innovation and enhancing patient care. We look forward to partnering with the Bayer Non-Viral Delivery team.” #pantherna #bayer #lnp #mrna #biotech #pharma #rnatherapeutics #nonviraldelivery

🚀 Exciting news from Islex Therapeutics, LLC! They have been awarded $275,000 by the National Science Foundation (NSF) under the National Science Foundation subagency. This funding will support their groundbreaking work on islet-targeted restorative therapy for Type 1 Diabetes. The project aims to demonstrate the efficacy and safety of beta-cell restorative therapeutics in preclinical studies, potentially leading to new therapeutic options for millions of patients worldwide. This innovation could significantly improve the quality of life for those with diabetes and reduce healthcare costs associated with diabetes-related complications. #SBIR #STTR #Innovation #Healthcare 🔬 The research, part of the Small Business Innovation Research Program Phase I, will focus on developing antibody therapeutics for the treatment of Stage 3 Type-1 Diabetes by harnessing the synergistic effects of autoimmune protection, insulin supplementation, and targeted delivery of mitogenic drugs to the pancreatic islet. The award will last for 11 months, starting on September 15, 2024, and ending on August 31, 2025. Kudos to Islex Therapeutics for their dedication to advancing diabetes treatment! #Biopharmaceuticals #Research #DiabetesCare